QQ客服 官方微博 反馈留言

	Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study
	Xu, Hongrong; Sheng, Lei; Chen, Weili; Yuan, Fei; Yang, Mengjie; Li, Hui; Li, Xuening; Choi, John; Zhao, Guiyu; Hu, Tianxin
刊名	DRUG DESIGN DEVELOPMENT AND THERAPY
	2016
卷号	10
关键词	HMS5552 glucokinase activator type 2 diabetes pharmacokinetics pharmacodynamics
ISSN号	1177-8881
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3625077
专题	复旦大学上海医学院
推荐引用方式 GB/T 7714	Xu, Hongrong,Sheng, Lei,Chen, Weili,et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study[J]. DRUG DESIGN DEVELOPMENT AND THERAPY,2016,10.
APA	Xu, Hongrong.,Sheng, Lei.,Chen, Weili.,Yuan, Fei.,Yang, Mengjie.,...&Chen, Li.(2016).Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study.DRUG DESIGN DEVELOPMENT AND THERAPY,10.
MLA	Xu, Hongrong,et al."Safety, tolerability, pharmacokinetics, and pharmacodynamics of novel glucokinase activator HMS5552: results from a first-in-human single ascending dose study".DRUG DESIGN DEVELOPMENT AND THERAPY 10(2016).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。